193 related articles for article (PubMed ID: 36152763)
1. Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury.
Chalasani N; Li YJ; Dellinger A; Navarro V; Bonkovsky H; Fontana RJ; Gu J; Barnhart H; Phillips E; Lammert C; Schwantes-An TH; Nicoletti P; Kleiner DE; Hoofnagle JH;
J Hepatol; 2023 Feb; 78(2):293-300. PubMed ID: 36152763
[TBL] [Abstract][Full Text] [Related]
2. Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury.
de Boer YS; Kosinski AS; Urban TJ; Zhao Z; Long N; Chalasani N; Kleiner DE; Hoofnagle JH;
Clin Gastroenterol Hepatol; 2017 Jan; 15(1):103-112.e2. PubMed ID: 27311619
[TBL] [Abstract][Full Text] [Related]
3. Nitrofurantoin-induced liver injury: long-term follow-up in two prospective DILI registries.
Bessone F; Ferrari A; Hernandez N; Mendizabal M; Ridruejo E; Zerega A; Tanno F; Reggiardo MV; Vorobioff J; Tanno H; Arrese M; Nunes V; Tagle M; Medina-Caliz I; Robles-Diaz M; Niu H; Alvarez-Alvarez I; Stephens C; Lucena MI; Andrade RJ
Arch Toxicol; 2023 Feb; 97(2):593-602. PubMed ID: 36416910
[TBL] [Abstract][Full Text] [Related]
4. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.
Chalasani N; Bonkovsky HL; Fontana R; Lee W; Stolz A; Talwalkar J; Reddy KR; Watkins PB; Navarro V; Barnhart H; Gu J; Serrano J;
Gastroenterology; 2015 Jun; 148(7):1340-52.e7. PubMed ID: 25754159
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study.
Chalasani N; Bonkovsky HL; Stine JG; Gu J; Barnhart H; Jacobsen E; Björnsson E; Fontana RJ; Kleiner DE; Hoofnagle JH;
J Hepatol; 2022 Apr; 76(4):832-840. PubMed ID: 34953957
[TBL] [Abstract][Full Text] [Related]
6. A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry.
Björnsson ES; Stephens C; Atallah E; Robles-Diaz M; Alvarez-Alvarez I; Gerbes A; Weber S; Stirnimann G; Kullak-Ublick G; Cortez-Pinto H; Grove JI; Lucena MI; Andrade RJ; Aithal GP
Liver Int; 2023 Jan; 43(1):115-126. PubMed ID: 35899490
[TBL] [Abstract][Full Text] [Related]
7. Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor.
Urban TJ; Nicoletti P; Chalasani N; Serrano J; Stolz A; Daly AK; Aithal GP; Dillon J; Navarro V; Odin J; Barnhart H; Ostrov D; Long N; Cirulli ET; Watkins PB; Fontana RJ; ; ;
J Hepatol; 2017 Jul; 67(1):137-144. PubMed ID: 28323125
[TBL] [Abstract][Full Text] [Related]
8. HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury.
Nicoletti P; Werk AN; Sawle A; Shen Y; Urban TJ; Coulthard SA; Bjornsson ES; Cascorbi I; Floratos A; Stammschulte T; Gundert-Remy U; Nelson MR; Aithal GP; Daly AK;
Pharmacogenet Genomics; 2016 May; 26(5):218-24. PubMed ID: 26959717
[TBL] [Abstract][Full Text] [Related]
9. Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-Clavulanate.
Nicoletti P; Dellinger A; Li YJ; Barnhart HX; Chalasani N; Fontana RJ; Odin JA; Serrano J; Stolz A; Etheridge AS; Innocenti F; Govaere O; Grove JI; Stephens C; Aithal GP; Andrade RJ; Bjornsson ES; Daly AK; Lucena MI; Watkins PB; ; ;
Gastroenterology; 2023 Mar; 164(3):454-466. PubMed ID: 36496055
[TBL] [Abstract][Full Text] [Related]
10. Single-nucleotide polymorphisms of
Yang WN; Pang LL; Zhou JY; Qiu YW; Miao L; Wang SY; Liu XZ; Tan KA; Shi WW; Wang GQ; Hou FQ
World J Gastroenterol; 2020 Mar; 26(12):1329-1339. PubMed ID: 32256020
[TBL] [Abstract][Full Text] [Related]
11. Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis: the influence of human leucocyte antigen alleles.
Stephens C; Castiella A; Gomez-Moreno EM; Otazua P; López-Nevot MÁ; Zapata E; Ortega-Alonso A; Ruiz-Cabello F; Medina-Cáliz I; Robles-Díaz M; Soriano G; Roman E; Hallal H; Moreno-Planas JM; Prieto M; Andrade RJ; Lucena MI
Pharmacogenet Genomics; 2016 Sep; 26(9):414-22. PubMed ID: 27206238
[TBL] [Abstract][Full Text] [Related]
12. Relapse and Need for Extended Immunosuppression: Novel Features of Drug-Induced Autoimmune Hepatitis.
Weber S; Gerbes AL
Digestion; 2023; 104(3):243-248. PubMed ID: 36603570
[TBL] [Abstract][Full Text] [Related]
13. Drug-induced liver injury (DILI) ascribed to non-steroidal anti-inflammatory drugs (NSAIDs) in the USA-Update with genetic correlations.
Bonkovsky HL; Ghabril M; Nicoletti P; Dellinger A; Fontana RJ; Barnhart H; Gu J; Daly AK; Aithal GP; Phillips EJ; Kleiner DE;
Liver Int; 2024 Jun; 44(6):1409-1421. PubMed ID: 38451034
[TBL] [Abstract][Full Text] [Related]
14. Leflunomide-induced liver injury: Differences in characteristics and outcomes in Indian and US registries.
Devarbhavi H; Ghabril M; Barnhart H; Patil M; Raj S; Gu J; Chalasani N; Bonkovsky HL
Liver Int; 2022 Jun; 42(6):1323-1329. PubMed ID: 35129282
[TBL] [Abstract][Full Text] [Related]
15. Value of liver biopsy in the diagnosis of drug-induced liver injury.
Ahmad J; Barnhart HX; Bonacini M; Ghabril M; Hayashi PH; Odin JA; Rockey DC; Rossi S; Serrano J; Tillmann HL; Kleiner DE;
J Hepatol; 2022 May; 76(5):1070-1078. PubMed ID: 35074471
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry.
Stephens C; Robles-Diaz M; Medina-Caliz I; Garcia-Cortes M; Ortega-Alonso A; Sanabria-Cabrera J; Gonzalez-Jimenez A; Alvarez-Alvarez I; Slim M; Jimenez-Perez M; Gonzalez-Grande R; Fernández MC; Casado M; Soriano G; Román E; Hallal H; Romero-Gomez M; Castiella A; Conde I; Prieto M; Moreno-Planas JM; Giraldez A; Moreno-Sanfiel JM; Kaplowitz N; Lucena MI; Andrade RJ;
J Hepatol; 2021 Jul; 75(1):86-97. PubMed ID: 33539847
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced liver injury with autoimmune features.
deLemos AS; Foureau DM; Jacobs C; Ahrens W; Russo MW; Bonkovsky HL
Semin Liver Dis; 2014 May; 34(2):194-204. PubMed ID: 24879983
[TBL] [Abstract][Full Text] [Related]
18. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases.
Ghabril M; Bonkovsky HL; Kum C; Davern T; Hayashi PH; Kleiner DE; Serrano J; Rochon J; Fontana RJ; Bonacini M;
Clin Gastroenterol Hepatol; 2013 May; 11(5):558-564.e3. PubMed ID: 23333219
[TBL] [Abstract][Full Text] [Related]
19. Corticosteroid plus glycyrrhizin therapy for chronic drug- or herb-induced liver injury achieves biochemical and histological improvements: a randomised open-label trial.
Wang JB; Huang A; Wang Y; Ji D; Liang QS; Zhao J; Zhou G; Liu S; Niu M; Sun Y; Tian H; Teng GJ; Chang BX; Bi JF; Peng XX; Xin S; Xie H; Ma X; Mao YM; Liangpunsakul S; Saxena R; Aithal GP; Xiao XH; Zhao J; Zou Z
Aliment Pharmacol Ther; 2022 May; 55(10):1297-1310. PubMed ID: 35362188
[TBL] [Abstract][Full Text] [Related]
20. A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury.
Cirulli ET; Nicoletti P; Abramson K; Andrade RJ; Bjornsson ES; Chalasani N; Fontana RJ; Hallberg P; Li YJ; Lucena MI; Long N; Molokhia M; Nelson MR; Odin JA; Pirmohamed M; Rafnar T; Serrano J; Stefánsson K; Stolz A; Daly AK; Aithal GP; Watkins PB; ;
Gastroenterology; 2019 May; 156(6):1707-1716.e2. PubMed ID: 30664875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
